From October 28 to 30, 2025, the highly anticipated CPHI Worldwide 2025 was successfully held in Frankfurt, Germany. As a leading Chinese manufacturer with sustained global influence in the Cephalosporin API sector, Titan Pharmaceutical Co., Ltd.(Guangdong) once again took the stage at this international event. Together with its sister company, Lijian Pharma, Titan Pharmaceutical met with formulation manufacturers, importers, and partners from Europe, Turkey, and several Middle Eastern countries.

During the exhibition, Titan Pharmaceutical showcased its strong technical capabilities, robust quality system, and global supply strength in Cephalosporin APIs, reinforcing its long-term commitment to high-quality and reliable international cooperation.

Throughout the event, Titan Pharmaceutical’s booth remained highly active, attracting a wide range of potential partners from key pharmaceutical markets — particularly in Europe, Turkey, the Middle East, and Latin America. The company’s two flagship products, Cefuroxime Sodium Sterile and Cefuroxime Axetil Amorphous, continued to draw strong interest and became the core topics of business discussions.

Most conversations focused on product specifications and batch stability, regulatory documentation support, and annual order planning. This trend highlights the steady rise in global demand for Cephalosporin APIs and a clear shift in cooperation models toward long-term partnerships supported by regulatory compliance.

In addition, this year’s participation was a joint effort between Titan Pharmaceutical and its sister company Lijian Pharma, showcasing their full-process capabilities across the Cephalosporin API value chain — from R&D and manufacturing to quality systems, regulatory documentation support, and global market cooperation. This collaboration further strengthens the group’s presence and influence within the international pharmaceutical supply chain.

Looking ahead, Titan Pharmaceutical will continue to follow its core strategy of “long-term supply · global compliance · quality first”, driving the steady expansion of its Cephalosporin API business in international markets. With a broader global vision and stronger technical capability, the company aims to reach more countries and regions, and looks forward to meeting its global pharmaceutical partners again in the near future.